Latest Galapagos Genomics N (GLPGF) Headlines
Post# of 3
Posted On: 03/10/2014 12:21:47 AM
Latest Galapagos Genomics N (GLPGF) Headlines
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
PR Newswire - Fri May 17, 12:15AM CDT
Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities.
Galapagos announces receipt of EUR2.7m IWT grant for antibacterial research
M2 - Thu Jan 10, 5:22AM CST
Galapagos NV (Euronext:GLPG)(OTC:GLPGF), a mid-size clinical stage biotechnology company, announced today the award of a EUR2.7m grant from the Flemish agency for Innovation by Science and Technology (IWT) to discover new antibiotic treatments.
AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease
PR Newswire - Fri May 17, 12:15AM CDT
Galapagos NV (Euronext: GLPG) and AbbVie (NYSE: ABBV) announced today an extension of their GLPG0634 clinical development collaboration to include Crohn's disease. Galapagos will fund and complete a Phase 2 program in Crohn's disease, which is designed to facilitate rapid progression into Phase 3. Upon successful completion of the study, expected in Q2 2015, AbbVie will pay Galapagos $50 million. The terms of the collaboration extension are in addition to previously agreed upon financial terms. AbbVie will be responsible for funding and performing clinical development beyond Phase 2, and completing regulatory and commercialization activities.
Galapagos announces receipt of EUR2.7m IWT grant for antibacterial research
M2 - Thu Jan 10, 5:22AM CST
Galapagos NV (Euronext:GLPG)(OTC:GLPGF), a mid-size clinical stage biotechnology company, announced today the award of a EUR2.7m grant from the Flemish agency for Innovation by Science and Technology (IWT) to discover new antibiotic treatments.
(0)
(0)Galapagos Genomics N (GLPGF) Stock Research Links
Scroll down for more posts ▼